ERDERA officially announced the supported projects of the 2025 call 

The European Rare Diseases Research Alliance (ERDERA) has published the results of its first Joint Transnational Call (JTC 2025) focused on the preclinical development of therapies for rare diseases: Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation.

Eighteen international research projects were selected under the call, which will receive total funding of approximately €29 million. Twenty-nine national and regional funding agencies from 23 countries participated in the call, with the projects being co-financed by the European Commission. 

The selected projects focus on a wide range of serious and often life-limiting rare diseases—from epilepsy with early-onset neurological disorders to rare heart diseases, immune system disorders, and fibrotic lung diseases. The aim is to accelerate the transfer of promising preclinical results into future clinical trials and contribute to the development of safer and more effective therapies for patients with rare diseases. Detailed information on individual projects is available in the official press release or on the ERDERA website.